As a recently recognized hallmark of cancer (D. Hanahan; RA. Weinberg; Cell 144 , March 4, 2011), the immune system plays a major role in the multistep development of human tumors. Immune-based therapies are emerging in the clinical practice and represent now one of the main spotlights for the biotech and pharma industry.
There are today more than 500 open immunotherapy trials (https://clinicaltrials.gov) with a number of different strategies from check point inhibitors, as single agent or combined together or with other standard therapies, to cell therapies and vaccines approaches. The first immunotherapies approved have all in common an efficacy restricted to only a small subset of patients. This drawback impacts the drug development process and ultimately the overall economic equation when the drug reaches the market.
HalioDx anticipates a bright future for immune-oncology diagnostics which provide the relevant clinical information such as:
HalioDx believes that measuring selected biomarkers shaping the “Immune Contexture” of tumors (Fridman WH et al. Nature Reviews Cancer 12, 298-306) such as immune cells and molecular immune effectors will maximize the potential of standards therapies and immunotherapies for the benefit of patients and national health systems.
HalioDx utilizes a proprietary set of Immune biomarkers, advanced image analysis technologies and a unique know-how to develop, manufacture and commercialize immune-based diagnostics services and products.